• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    CHIEF FINANCIAL OFFICER Feeley Kevin converted options into 717 shares and sold $47,556 worth of shares (378 units at $125.81), increasing direct ownership by 9% to 4,096 units (SEC Form 4)

    9/3/25 6:31:59 PM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology
    Get the next $WGS alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Feeley Kevin

    (Last) (First) (Middle)
    C/O GENEDX HOLDINGS CORP.
    333 LUDLOW ST, NORTH TOWER, 6TH FLOOR

    (Street)
    STAMFORD CT 06902

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    GeneDx Holdings Corp. [ WGS ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    CHIEF FINANCIAL OFFICER
    3. Date of Earliest Transaction (Month/Day/Year)
    09/01/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Class A Common Stock 09/01/2025 M 717 A $0(1) 4,474 D
    Class A Common Stock 09/02/2025 S(2) 378 D $125.8096(3) 4,096(4) D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Restricted Stock Unit (1) 09/01/2025 M 717 (5) (5) Class A Common Stock 717 $0 2,869 D
    Explanation of Responses:
    1. Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration.
    2. The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sales were to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
    3. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $125.80 to $126.2050 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
    4. Following the reported sales, in addition to the 4,096 shares of Class A common stock beneficially owned by the Reporting Person, the Reporting Person beneficially owned restricted stock units ("RSUs") representing contingent rights to receive up to an aggregate of 134,292 shares of Class A common stock and options to purchase up to an aggregate of 27,152 shares of Class A common stock, which RSUs and options vest according to their respective terms.
    5. 6.25% vest in quarterly installments over the 4-year period commencing on December 1, 2022 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.
    /s/ Bridget Brown, Attorney-in-Fact 09/03/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $WGS alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $WGS

    DatePrice TargetRatingAnalyst
    7/9/2025$110.00Overweight
    Piper Sandler
    5/15/2025$88.00Buy
    Guggenheim
    5/9/2025$80.00Hold → Buy
    Jefferies
    8/28/2024$34.00Equal Weight
    Wells Fargo
    7/10/2024$43.00Buy
    Craig Hallum
    6/3/2024$21.00Hold
    Jefferies
    More analyst ratings

    $WGS
    SEC Filings

    View All

    SEC Form POS AM filed by GeneDx Holdings Corp.

    POS AM - GeneDx Holdings Corp. (0001818331) (Filer)

    9/5/25 7:03:48 AM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    SEC Form 144 filed by GeneDx Holdings Corp.

    144 - GeneDx Holdings Corp. (0001818331) (Subject)

    8/27/25 5:20:10 PM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    SEC Form 144 filed by GeneDx Holdings Corp.

    144 - GeneDx Holdings Corp. (0001818331) (Subject)

    8/22/25 7:14:16 PM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    $WGS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Piper Sandler initiated coverage on GeneDx with a new price target

    Piper Sandler initiated coverage of GeneDx with a rating of Overweight and set a new price target of $110.00

    7/9/25 8:30:02 AM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    Guggenheim initiated coverage on GeneDx with a new price target

    Guggenheim initiated coverage of GeneDx with a rating of Buy and set a new price target of $88.00

    5/15/25 8:11:58 AM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    GeneDx upgraded by Jefferies with a new price target

    Jefferies upgraded GeneDx from Hold to Buy and set a new price target of $80.00

    5/9/25 8:38:50 AM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    $WGS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Meister Keith A. bought $3,007,997 worth of shares (50,000 units at $60.16) (SEC Form 4)

    4 - GeneDx Holdings Corp. (0001818331) (Issuer)

    5/16/25 4:00:06 PM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    Director Meister Keith A. bought $5,600,994 worth of shares (100,000 units at $56.01) (SEC Form 4)

    4 - GeneDx Holdings Corp. (0001818331) (Issuer)

    5/12/25 7:46:55 PM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    Casdin Capital, Llc bought $2,757,117 worth of shares (130,000 units at $21.21) (SEC Form 4)

    4 - GeneDx Holdings Corp. (0001818331) (Issuer)

    6/5/24 8:45:06 PM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    $WGS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $WGS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Seer Appoints Isaac Ro to its Board of Directors

    REDWOOD CITY, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced it has appointed Isaac Ro to serve on its Board of Directors. "We are excited to welcome Isaac to our board," said Omid Farokhzad, Chair and CEO of Seer. "Isaac brings a rare combination of financial leadership and deep sector experience across life science tools, diagnostics, and the broader healthcare ecosystem. His proven track record of guiding companies through transformative growth will be invaluable as we continue to execute on key milestones and accelerate the impact of our platform." "I'm looking forward to work

    9/2/25 7:00:00 AM ET
    $SEER
    $WGS
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Retail: Computer Software & Peripheral Equipment
    Technology

    GeneDx to Participate in Upcoming Investor Conferences

    GeneDx (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic insights, today announced that company management will participate in upcoming investor conferences: Canaccord Genuity's 45th Annual Growth Conference Boston, Massachusetts Fireside chat: Tuesday, August 12 at 8:00 a.m. ET 2025 Wells Fargo Healthcare Conference Boston, Massachusetts Fireside chat: Thursday, September 4 at 2:15 p.m. ET Morgan Stanley 23rd Annual Global Healthcare Conference New York, New York Fireside chat: Monday, September 8 at 8:30 a.m. ET Live and archived webcasts of the presentations will be available on the "Events" section of the GeneDx investor relations website at ir.

    8/6/25 8:30:00 AM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    GeneDx Reports Second Quarter 2025 Financial Results and Business Highlights

    Reported second quarter 2025 revenues of $102.7 million with 69% year-over-year growth of exome and genome test revenue Expanded adjusted gross margin to 71% and generated adjusted net income1 of $15.0 million for the second quarter 2025 Raised guidance to deliver between $400 and $415 million in revenue with between 48% to 52% full year growth in exome and genome revenue Announced American Academy of Pediatrics (AAP) now recommends pediatricians use exome and genome testing as first-line for children with global developmental delay or intellectual disability Hosting conference call today at 8:30 a.m. ET GeneDx Holdings Corp. (NASDAQ:WGS), a leader in delivering improved hea

    7/29/25 6:30:00 AM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    CHIEF FINANCIAL OFFICER Feeley Kevin converted options into 717 shares and sold $47,556 worth of shares (378 units at $125.81), increasing direct ownership by 9% to 4,096 units (SEC Form 4)

    4 - GeneDx Holdings Corp. (0001818331) (Issuer)

    9/3/25 6:31:59 PM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    Director Ryan Jason sold $4,995,801 worth of shares (39,222 units at $127.37), decreasing direct ownership by 9% to 11,904 units (SEC Form 4)

    4 - GeneDx Holdings Corp. (0001818331) (Issuer)

    8/27/25 9:01:50 PM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    Director Casdin Capital, Llc sold $60,451,950 worth of shares (500,000 units at $120.90) (SEC Form 4)

    4 - GeneDx Holdings Corp. (0001818331) (Issuer)

    8/22/25 6:55:52 PM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    $WGS
    Financials

    Live finance-specific insights

    View All

    GeneDx Reports Second Quarter 2025 Financial Results and Business Highlights

    Reported second quarter 2025 revenues of $102.7 million with 69% year-over-year growth of exome and genome test revenue Expanded adjusted gross margin to 71% and generated adjusted net income1 of $15.0 million for the second quarter 2025 Raised guidance to deliver between $400 and $415 million in revenue with between 48% to 52% full year growth in exome and genome revenue Announced American Academy of Pediatrics (AAP) now recommends pediatricians use exome and genome testing as first-line for children with global developmental delay or intellectual disability Hosting conference call today at 8:30 a.m. ET GeneDx Holdings Corp. (NASDAQ:WGS), a leader in delivering improved hea

    7/29/25 6:30:00 AM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    GeneDx to Report Second Quarter 2025 Financial Results on Tuesday, July 29, 2025

    GeneDx (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic insights, today announced it will release financial results for the second quarter of 2025 before the market opens on Tuesday, July 29, 2025. Management will host a conference call that day to discuss second quarter 2025 financial and operating results at 8:30 a.m. Eastern Time. Conference Call Details Investors interested in listening to the conference call are required to register online. A live and archived webcast of the event will be available on the "Events" section of the GeneDx investor relations website at https://ir.genedx.com/. About GeneDx At GeneDx (NASDAQ:WGS), we believe that everyone

    7/10/25 8:30:00 AM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    GeneDx Reports First Quarter 2025 Financial Results and Business Highlights

    Reported first quarter 2025 revenues of $87.1 million with 62% year-over-year growth of exome and genome test revenue Generated first quarter 2025 adjusted net income1 of $7.7 million Announced plans to acquire Fabric Genomics Raised guidance to deliver between $360 and $375 million in revenue and reaffirmed outlook to deliver exome/genome volume and revenue growth of at least 30% in FY 2025 GeneDx to host conference call today at 8:30 a.m. ET GeneDx Holdings Corp. (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic insights, today reported its financial results for the first quarter of 2025. "Healthcare is at an inflection point where integrating genomic ins

    4/30/25 6:30:00 AM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    $WGS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by GeneDx Holdings Corp.

    SC 13D/A - GeneDx Holdings Corp. (0001818331) (Subject)

    11/20/24 9:36:13 PM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    Amendment: SEC Form SC 13D/A filed by GeneDx Holdings Corp.

    SC 13D/A - GeneDx Holdings Corp. (0001818331) (Subject)

    11/19/24 8:00:24 PM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    Amendment: SEC Form SC 13D/A filed by GeneDx Holdings Corp.

    SC 13D/A - GeneDx Holdings Corp. (0001818331) (Subject)

    11/8/24 5:23:34 PM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    $WGS
    Leadership Updates

    Live Leadership Updates

    View All

    Seer Appoints Isaac Ro to its Board of Directors

    REDWOOD CITY, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced it has appointed Isaac Ro to serve on its Board of Directors. "We are excited to welcome Isaac to our board," said Omid Farokhzad, Chair and CEO of Seer. "Isaac brings a rare combination of financial leadership and deep sector experience across life science tools, diagnostics, and the broader healthcare ecosystem. His proven track record of guiding companies through transformative growth will be invaluable as we continue to execute on key milestones and accelerate the impact of our platform." "I'm looking forward to work

    9/2/25 7:00:00 AM ET
    $SEER
    $WGS
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Retail: Computer Software & Peripheral Equipment
    Technology

    GeneDx Strengthens Executive Leadership Team with Bryan Dechairo Named Chief Operating Officer

    Experienced Diagnostics Executive with a Proven Record of Driving Business Growth to Lead Product & Technology, Operations, Medical Affairs, Innovation and More New Executive Leadership Positions Company for Growth and Scale GeneDx (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic insights, today announced the appointment of Bryan Dechairo as Chief Operating Officer, effective immediately. In the newly created role, Bryan will report to Katherine Stueland, CEO and President, and will serve on the company's executive leadership team. As Chief Operating Officer, Bryan will oversee Product & Technology, Operations, Medical Affairs, Innovation, and the Program

    1/2/25 4:01:00 PM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    GeneDx Announces Heidi Chen as Chief Legal Officer and Corporate Secretary

    Veteran Legal Executive from Zoetis and Pfizer Joins GeneDx Executive Leadership Team to Lead Legal, Compliance and Policy Functions GeneDx (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic insights, today announced the appointment of Heidi Chen as Chief Legal Officer, effective November 25, 2024. In her role, Heidi will report to Katherine Stueland, CEO and President, and will serve on the executive leadership team. With over 30 years of experience, Heidi will lead all legal, compliance, and policy functions at GeneDx and will provide strategic counsel on corporate governance, intellectual property, regulatory matters, federal policy, compliance and more.

    11/18/24 8:30:00 AM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology